The Psychedelic Business Summit convenes leaders across the research, product and services supply chain of the psychedelic industry for information sharing to build a stronger business community around a stable, investable, and responsibly scaled marketplace for psychedelic therapeutics and consumer products.
Early-stage companies and global drug discovery leaders developing innovative compounds and therapeutic platforms
Mature operators delivering care through clinics, treatment centers, retreats, and traditional medical and alternative wellness facilities
Legal and compliance experts advising the development and commercialization
Regulators and policymakers interested in shaping evolving market frameworks
Investors and strategic advisors deploying capital across the sector
The psychedelic industry stands at a pivotal moment. Scientific progress and clinical promise are accelerating, yet commercialization pathways remain fragmented and regulatory clarity continues to evolve. Investors and operators alike are seeking disciplined models for growth, compliance, and long-term viability.
The Psychedelic Business Summit bridges research and real-world operations to reduce uncertainty and advance infrastructure — from regulatory pathways and clinical standards to delivery models and capital formation.
Across multiple compounds and multiple delivery states, the Summit fosters practical dialogue and information sharing that supports responsible commercialization and sustainable industry growth and influence.
Above all, the Summit seeks to galvanize and inspire this community around the collective interest of advancing human health and wellness and making alternatives safe, affordable, and available across the entire population or afflicted and healthy individuals.
